MAIA

#4038
MAIA Biotechnology, Inc. Common Stock
1.3 2 USD
-0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
1.31
1.32
Jahresspanne
1.16
2.46
Tagesänderung
-0.75%
Monatliche Änderung
-4.35%
6 month change
-14.84%
Jahresänderung
-36.54%
Vorheriger Schlusskurs
1.3 3
Open
1.3 1
Tief
1.3 1
Hoch
1.3 2
Volumen
20
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Quarterly report, Q2 FY2026
MAIA Biotechnology, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
MAIA Biotechnology, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K

MAIA Biotechnology, Inc. current report, Q3 FY2025

Full document

MAIA Biotechnology, Inc. - Form 8-K Summary

Business Context and Reporting Period

MAIA Biotechnology, Inc. (MAIA), a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on September 11, 2025. The Company is headquartered in Chicago, Illinois, and its common stock trades on the NYSE American under the symbol "MAIA".

Key Financial Metrics

This filing is a Current Report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.

Material Changes and Events

Under Item 8.01 (Other Events), the Company announced the release of positive efficacy data from the Phase 2 Clinical Trial of its product candidate, THIO-101, in the treatment of Non-Small Cell Lung Cancer. This announcement was made via a press release dated September 11, 2025, which is attached as Exhibit 99.1.

Guidance, Outlook, and Risks

The filing includes extensive forward-looking statements regarding the Company's research and development programs. Management cautions that actual results may differ materially from expectations due to various risks, including:

  • The initiation, timing, cost, progress, and results of preclinical and clinical studies.
  • The ability to advance product candidates and successfully complete clinical studies.
  • The timing or likelihood of regulatory filings and approvals.
  • The ability to develop, manufacture, and commercialize product candidates.
  • Market acceptance and the size/growth potential of target markets.
  • The ability to obtain and maintain intellectual property protection.

The Company explicitly states it undertakes no obligation to publicly update or revise any forward-looking statements except as required by law.

Investor Verification Checklist

  • Review the full text of the press release (Exhibit 99.1) for specific statistical details regarding the THIO-101 Phase 2 trial efficacy data.
  • Verify the Company's current cash position and runway in the most recent 10-Q or 10-K filing, as this 8-K does not contain financial data.
  • Monitor upcoming regulatory interactions or presentations where the Company may discuss the next steps for THIO-101 based on this data.
  • Assess the impact of the "emerging growth company" status on the Company's financial reporting and disclosure obligations.

Nachrichten